Bristol-Myers announced that findings from a 24-week Phase 3 clinical study, published online in the latest issue of Diabetes Care, demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of HbA1c levels in treatment-naïve adult patients with newly diagnosed type 2 diabetes. The study also showed reductions in the secondary endpoint of fasting plasma glucose (FPG) and total body weight...

In a press release dated November 17, Sirona Biochem Corp. announced that results of their latest clinical trials showed the SGLT2 inhibitor dapagliflozin lowered levels of HbA1c blood sugar significantly more than the placebo, and that it was safe and well tolerated with no serious treatment-related adverse events. The dapagliflozin was effective in patients regardless of disease stage and was associated with continuous weight loss and lowered glycemia without significant hypoglycemia. Sirona Biochem is a Canadian biotech company...